This Viewpoint describes how the US Food and Drug Administration’s 2006 Unapproved Drugs Initiative may have unintentionally made generic drugs more expensive and inaccessible and proposes policy reforms to address the harms of those price increases.
This Special Communication summarizes published evidence about the causes of elevated prescription drug prices in the United States and proposes policy options to mitigate the effects of high prices while preserving incentives for development and innovation.
This commentary discusses a survey study published in JAMA Dermatology that described the changes in the prices of commonly prescribed dermatologic drugs at national chain pharmacies over a 6-year period.
This Viewpoint maintains that the US Food and Drug Administration (FDA) should have a more active role in the approval and marketing of off-patent pharmaceutical products.
This Viewpoint discusses the structure of the generic drug market in the United States and 3 different approaches that could stabilize it.
You currently have no searches saved.